India Supreme Court Bans Unproven Stem Cell Therapy for ASD
Analysis based on 7 articles · First reported Jan 30, 2026 · Last updated Jan 31, 2026
The ruling by the India===Supreme Court of India is expected to increase regulatory scrutiny on unproven medical treatments, potentially impacting clinics offering such services. It may also spur investment in approved clinical trials for stem cell therapies, benefiting entities involved in legitimate research.
The India===Supreme Court of India has ruled that stem cell therapies for Autism Spectrum Disorder (ASD) cannot be offered as a routine clinical service outside of approved and monitored clinical trials. The court deemed such practices unethical and medical malpractice due to a lack of scientific evidence regarding safety and efficacy. The ruling came in response to a petition filed by Yash Charitable Trust, which highlighted the rampant promotion of unproven stem cell treatments. The India===Supreme Court of India directed the India===Ministry of Health and Family Welfare, in consultation with AIIMS and the India===National Medical Commission, to devise a plan for patients currently undergoing these therapies to either continue treatment or transition to approved clinical trials. The court also emphasized the need for a consolidated legal framework for stem cell research in India, noting the current fragmented regulatory landscape.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard